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ABSTRACT  
Diabetes mellitus is associated with high morbidity and 
mortality among patients and its prevalence is increasing at an 
alarming rate worldwide. Insulin analogues are reported to have 
better efficacy and safety as compared to conventional insulin 
therapy, however, substantiation of data in different geographical 
areas with genomic variation is yet to be established. The study 
was aimed to evaluate and compare the effectiveness and 
clinical safety profile of insulin analogues with regular insulin. In 
this prospective, randomized, observational study conducted at 
a Superspeciality hospital in India,78 diabetic patients on insulin 
therapy were recruited. The efficacy and safety markers of 24 
patients on biphasic insulin analogue, 33 on recombinant insulin 
analogue and 21 on regular insulin were observed for 13 weeks. 
The collected data was statistically analyzed by using Instat 
software.The efficacy markers such as glycosylated hemoglobin, 
fasting and postprandial glucose values showed superior 
improvement with the insulin analogues at the end of 13 weeks 
study. Insulin analogues produced significantly fewer incidents 
of minor hypoglycemia without any significant alteration in BMI 
and weight gain. The results of our studies suggest that insulin 
analogues are safer and effective with regards to glycemic 
control and in the event of hypoglycemia over regular insulin. 
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INTRODUCTION 
Diabetes mellitus is a chronic metabolic 
disorder and its prevalence is increasing at an 
alarming rate especially in low and middle 
income nations. According to International 
Diabetes Federation, number of diabetic 
patients will rise from an estimated 285 million 
in 2010 to approximately 438 million in 2030 
(International Diabetes Federation, 2009). India 
ranks first in prevalence of diabetes and as per 
the WHO estimate there will be around 87 
million diabetics in India by the year 2030 
(Bjork et al., 2003). Diabetes places a 
considerable burden on national economy and 
also if left uncontrolled, serious complications 
ensue that present larger morbid conditions 
which often result in mortality. Thus good 
glycemic control, to maintain glycosylated 
hemoglobin (HbA1c) concentration of 7% or 
less, must be observed to reduce the risk of 
development of the severe complications 
(American Diabetes Association, 2014). 
Current therapeutic approaches, 
pharmacological and life style modifications, 
merely control the condition and the therapy is 
needed lifelong (Dipiro et al., 2008). Insulin is 
the original and most effective treatment to 
manage type 1 and type 2 diabetes if exercise, 
diet or oral hypoglycemic agents failed to 
achieve the normal glycemia (Canadian Diabetes 
Association, 2003). The pharmacokinetics 
following subcutaneous injection of the 
currently available rapid, intermediate and long 
acting insulin preparations are unable to 
achieve normoglycemia because these agents do 
not replicate the pattern of basal and 
postprandial endogenous secretion of insulin in 
normal subjects in responds to a meal (Das and 
Moses, 2007). The direct effect of secreted 
insulin on hepatic metabolic processes is 
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eliminated due to diffusion of insulin in to the 
peripheral circulation. This limitation of insulin 
is addressed by developing modified human 
insulins or insulin analogues which differs by 
one or a few amino acids from primary 
structure of insulin. These mimic physiologic 
insulin action more closely than conventional 
human regular insulin preparations (Rosenstock 
et al., 2006). 
Majority of Type 2 diabetic patients 
require insulin therapy either conventional or 
insulin analogs due to destruction of β-cells in 
pancreas. Insulin lispro, aspart and glulusine are 
rapid acting insulin analogues and Insuin 
glargine and detemir are long acting analogues 
of insulin presently available in Indian market. 
The insulin analogs have similar potency as per 
dose by dose in comparison with conventional 
insulin, therefore, it is a common practice to 
use biphasic insulin twice/ thrice daily or 
biphasic human insulin twice a day with rapid 
acting human insulin before lunch (Holman et 
al., 2009).  In various studies conducted all over 
the world, Insulin analogues are reported to 
have better efficacy and safety as compared to 
regular insulin therapy (Singh et al., 2009), 
however, substantiation of data in different 
geographical areas with genomic variation is yet 
to be established.  
The aim of this study was therefore, to 
evaluate and compare the effectiveness and 
clinical safety profile of insulin analogues with 
regular insulin in North Indian population. 
 
MATERIAL AND METHODS 
This prospective, observational study 
was conducted on randomly selected diabetic 
patients on insulin therapy at outpatient 
department (OPD) of a superspeciality hospital 
in New Delhi, India. The aim of the study was 
to evaluate and compare the short term 
effectiveness and clinical safety profile of 




The study aim, objectives, duration and 
procedure were explained to the prospective 
participants and a signed informed consent 
form was obtained from 94 diabetic patients on 
insulin therapy. Exclusion criteria for the study 
included if patients were  mentally challenged, 
pregnant, below 18 years, on both insulin and 
oral hypoglycemic agents, refuse or unable to 
comply. Based on inclusion/exclusion criteria 
only 78 patients were enrolled in the study. 
There were 24 patients on biphasic insulin 
analogues, 33 on recombinant insulin analogues 
and 21 on regular insulin therapy at the 
commencement of the study. All the patients 
were observed for duration of 13 weeks. 
 
Data collection 
Data was collected from the physicians 
prescribing records, pathology lab reports and 
patient’s medical profile. At the 
commencement of the study parameters such 
as base line height, weight, body mass index 
(BMI), blood pressure, insulin dose, number of 
major/minor hypoglycemic events, recent 
HbA1c, serum glucose: fasting and postprandial 
etc of the recruited patients were measured.  
The efficacy of the insulin and its 
analogues was assessed on the basis of HbA1c, 
fasting and postprandial glucose values. Safety 
was assessed on the basis of hypoglycemic 
events (both minor and major) and weight 
changes during insulin therapy.  
 
Ethical consideration 
The study protocol was approved by 
institutional review board of Jamia Hamdard 
and by the ethical committee of Indraprastha 
Apollo hospital, New Delhi, India. Also all the 
enrolled patients were ensured confidentiality. 
 
Statistical analysis 
The statistical analyses were performed 
using Instat software. Student’s t test and 
Pearson Chi square tests were used to check 
the level of significance. Values of P< 0.005 
and 0.05 were considered highly significant and 
significant respectively.   
 
RESULTS AND DISCUSSION 
During the 13 weeks study period, a total 
of 78 patients, randomized in three groups; 
Biphasic Analogues (BA), Insulin analogues 
(IA) and Regular Insulin (RI) (24, 33 and 21 
patients respectively) completed the study. 
Duration of present study was comparatively 
shorter, but as per literature survey          
reports, efficacy and safety evaluation data 
exists  of  similar study duration (Breizel, 2004).  
Substantiation on Short Term Efficacy 
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Table I. Base line characteristics of participants 
 
Parameters BA IA RI p- value 
OPD (numbers) 24 33 21 0.223 
Age (years) 50.42±1.54 56.52±2.21 51.71±1.95  
Sex (M/F) 14/10 21/12 9/12 0.89 
BMI (kg/m2) 24.55±0.47 26.70±0.75 24.98±0.79  
Type of DM (Type 2/Type 1) 24/0 30/3 21/0 <0.001 
Diabetes duration (months) 33.25±3.31 66.39±8.89 63.43±11.60  
Complications (Micro/Macro) 3/1 9/6 6/1 0.96 
Patients classification based 
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Data on; age, Body Mass Index (BMI) and diabetes duration is expressed as Mean ± SEM. p-value by Chi 
square test;BA = Biphasic Insulin analogue, IA = Insulin an 
alogue, RI = Regular Insulin. 
 
The base line characteristics such as age, BMI, 
type of DM, diabetes duration (in months), 
complications (micro/macro) of the three 
groups are presented in table I.  
Majority of the participants were male 
(44/78) and were suffering from type 2 
diabetes. The mean age of the patients was 
more than 50 years but in previous similar 
studies mean age was less than 50 years (Home, 
2004). Male, female ratio varied between the 
three groups but female patients were 
comparatively more in RI group. Mean BMI 
value in BA and RI treatment groups was less 
than 25 kg/m2, whereas in IA group the value 
was more than 26 kg/m2.  
Mean value of diabetes duration in 
present study was more than that of previous 
study (Freeman, 2010). Study participants were 
also classified on the basis of their blood 
pressure and diabetic diet intake. One third of 
the study population was hypertensive and 
approximately 80% of the diabetic patients 
were consuming less than 1800 calories/day as 
per the physician’s advice and Pearson Chi 
square test revealed no significant difference in 
their dietary intake (p<0.05) (Table I). 
Efficacy of the insulin therapy in three 
treatment groups was evaluated by measuring 
HbA1c level, a marker for predicting the 
glycemic control. A significant improvement in 
the overall glycemic control was observed in 
both BA and IA groups as evidenced by 
decrease in HbA1c levels from 9.94±0.40 to 
8.22 ±0.397 (p<0.005) and 9.94±0.53 to 
8.23±0.29 (p<0.005) respectively. Regular 
Insulin was not effective as analogues in terms 
of glycemic control that was probably due to 
different baseline HbA1c levels in three treated 
groups. The RI treated subjects had much 
lower baseline HbA1c level as compared to 
other two groups, thus it would be very 
difficult to reduce the HbA1c levels any further. 
It was also observed that there was a significant 
percentage reduction in HbA1c (17.3% and 
17.2% in BA and IA group respectively)                 
in analogue groups, but percentage reduction  
in RI group was non-significant (2.3%) during 
the   13  weeks   of   Insulin  therapy (Table II).  
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Table II. Effect of insulin therapy on safety and efficacy parameters 
 





































































































-  9.87 
 
BA = Biphasic Insulin analogue, IA = Insulin analogue, RI = Regular Insulin, SEM = Standard Error of 
Mean. 
** Highly significant P< 0.005, * Significant P< 0.05, ns Not significant P> 0.05, Data on 13th week compared 
with that on 1st week by student’ t’ test. 
 
An overall statistically significant difference was 
also noted in the percentage reduction of              
BA versus RI and IA versus RI groups (Table 
III). The mean reduction from base line 
between BA and IA was found to be non 
significant. 
The mean fasting blood glucose (FBS) 
level decreased from 194.29 to 138.15 after 13 
weeks of treatment with IA. However, BA and 
RI failed to reduce the FBS level in the 
respective treatment groups. Thus it can be 
inferred that IA is superior to BA and RI in 
controlling the FBS level because of its 
pronounced effect on FBS percentage 
reduction (28.9%). A statistically significant 
difference was observed in between BA vs RI 
and BA vs IA when FBS percentage reduction 
was compared between groups (Table III). 
In case of postprandial blood sugar 
(PPBS), percentage reduction was more 
pronounced in BA group (29.2%) closely 
followed by RI group (20.1%). No significant 
improvement in PPBS was noted in case of 
insulin analogue group. (Table II and III) 
There was no significant difference 
observed in both, weight and insulin dosage 
requirements in the patients at the start or 
during 13 weeks of therapy. The mean initial 
dose requirement in analogue group was 
slightly higher than the RI and BA therapy 
groups. At the end of the study mean insulin 
daily dose was reduced in BA and IA groups 
while the opposite is observed in RI group 
where dose is increased to manage the 
hyperglycemia. Among all the groups, BA 
patients received the least Insulin dose (33.52-
32.57 units/day) and IA group was 
administered the highest dose (57.18-50.88 
units/day). A statistically significant difference 
was observed when insulin dose percentage 
reduction was compared between groups 
(Table III). 
None of the patients on insulin therapy 
reported any major hypoglycemic episode or 
serious adverse event. Total number of             
minor hypoglycemic episodes reported was      
4, 7 and 11 in BA, IA and RI respectively              
(i.e. RI> IA> BA) (Table 4). A total of 22 ADR 
were reported and were classified as 22.7% 
highly probable, 45.45% probable, 27.30% 
possible and 4.45 unlikely as per Naranjo’s scale 
(Table V). 
Substantiation on Short Term Efficacy 
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Table III. Comparison of percentage reduction of efficacy parameters between treated groups 
 
BA vs IA 
(Percentage reduction) 
BA vs RI 
(Percentage reduction) 
IA vs RI 
(Percentage reduction) 
Parameters 









































































BA = Biphasic Insulin analogue, IA = Insulin analogue, RI = Regular Insulin, SEM = Standard Error of 
Mean; ** Highly significant P< 0.005, * Significant P< 0.05, ns Not significant P> 0.05, Percentage reduction 
data of IA compared with BA,  RI with BA, and RI with IA by student’ t’ test. 
 
Table IV. Number of ADRs observed among diabetic patients  
 
Hypoglycemia (Number of events) BA IA RI 
Major 0 0 0 
Minor 4 7 11 
Nocturnal 0 0 0 
SAE 0 0 0 
 
Table V Classification of 22 cases of ADRs according to Naranjo’s ADR probability scale 
  
Assessment score Number of ADRs % of ADRs 
Unlikely; ≤ 0 1 4.45% 
Possible; 1-4 6 27.30% 
Probable; 5-8 10 45.45% 
Highly probable; ≥ 9 5 22.72% 
Total 22 100 
 
Regular insulin has been the main stay of 
therapy in diabetes since the introduction but 
due to its relatively slow onset of action, 
subcutaneous injection 30 to 60 minutes before 
meals is required to be administered. 
Administration of regular insulin is not only 
inconvenient and unrealistic, but it poses a risk 
of pre meal hypoglycemia if the meal is delayed 
or early postprandial hyperglycemia if the 
injection is at meal time (Rosenstock et al., 
2006). The disadvantages of the available 
conventional insulin preparations especially 
with regard to their time action profiles hamper 
the optimal implementation of intensive insulin 
therapy (Pickup and Williams, 2003). 
Therefore, newer insulin preparations having 
better efficacy, safety and versatility were 
developed and introduced into the therapy. 
Mohammad Ali Koladi 
Volume 25 Issue 3 (2014) 179 
Findings of a study conducted in 2010,                
that compared analogue and human insulin              
in controlled clinical trials and large 
observational studies indicate that insulin 
analogues provide objective benefits such               
as improved glycemic control, lower risk                 
of hypoglycemia and reduced weight                   
gain ((Freeman, 2010). These Insulin analogues 
may be an option for patients with problematic 
hypoglycemia.  
In our 13 weeks of evaluation of three 
different types of insulin therapy, significant 
reduction in the HbA1c values was obtained in 
BA and IA patients as compared to the values 
with RI therapy.  There was no significant 
difference observed between BA and IA in the 
% reduction of HbA1c values but IA group 
showed marked decrease in FBS level as 
compared to other two groups. However, IA 
could not match the BA and RI in controlling 
the PPBS level. The findings of our pilot study 
on efficacy parameters are in accordance with 
the earlier published reports (Breizel et al., 2004; 
Qayyum et al., 2008; Dills, 2001). 
There were no significant clinical 
differences observed in safety parameters 
among the three groups such as body weight, 
insulin dose, major or nocturnal hypoglycemic 
episodes and serious adverse events during            
the study period. The numbers of                   
minor hypoglycemic episodes reported in RI 
group was comparatively higher than BA and 
IA.  
The data of this study support evidence 
that analogues are safer and effective choice to 




The results of the present study 
demonstrate that insulin analogues are safer 
and effective with regards to glycemic control 
and event of hypoglycemia over regular insulin. 
Biphasic analogues are effective in glycemic 
control in terms of both HbA1c and PPBS, 
where as monophasic insulin analogues are 
effective in glycemic control in terms of both 
FBS and HbA1c. These analogues are safer than 
regular insulin as they produced less number of 
minor hypoglycemic episodes.  
 
LIMITATIONS OF THIS STUDY AND 
RECOMMENDATION 
Considering the limitations such as short 
study duration and study population size, 
findings of the study cannot be generalized to 
the North Indian population. Further detailed 
investigation is required for the safety and 
effectiveness evaluation, separately in basal and 
meal time analogues. 
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